Netherlands· NL-aa4db4e7175a

Lorviqua, 100 mg filmomhulde tabletten

A lorlatinib product containing lorlatinib, registered in Netherlands by Pfizer Limited. The same ATC class is registered in 13 of our 19 countries.

ATC L01ED05

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about lorlatinibAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Lorlatinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01ED05 (lorlatinib), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search lorlatinib products by name

Lorlatinib · ATC L01ED05

13 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lorlatinib costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), the median price runs from $0.31 in France to $192.44 in Switzerland — a ×614 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Lorlatinib · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

CH Switzerland$192.44
FR France$0.31

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: LORLATINIB
Manufacturer: Pfizer Limited
Country: Netherlands (NL)
ATC code: L01ED05
ATC class: Lorlatinib
Defined daily dose: 0.1 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/19/1355

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

570 interactions on record for lorlatinib.

Graded by severity as the source publishes them — 119 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check lorlatinib against other medicines How interaction checks work

Lorlatinib · interactions on record

570 records

119 severe
439 moderate
12 minor

Most severe, free to view

LonafarnibA16AX20severe
BerotralstatB06AC06severe
VoxelotorB06AX03severe
RanolazineC01EB18severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lorlatinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lorlatinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Lorviqua
Liechtenstein · Lorviqua
Norway · Lorviqua

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/b51a7209-8b2c-4ecc-a15c-d866b2100c37
GET /v1/drugs/b51a7209-8b2c-4ecc-a15c-d866b2100c37?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Lorlatinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp122499",
  "excipients": [
    "CALCIUMWATERSTOFFOSFAAT 0-WATER (E 341)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "GLYCEROLTRIACETAAT (E 1518)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "LACTOSE 1-WATER",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "LORLATINIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2019/05/06",
  "procedure_number": "EMEA/H/C/004646",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/19/1355",
  "additional_monitoring": "Y"
}

API reference MCP server Plans

See everything about lorlatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console